Garg Vipin K 4

What Happened
Vipin K. Garg, a director of Altimmune, had 42,050 restricted stock units (RSUs) convert into common shares on January 25, 2026. The conversion is reported as an exercise/conversion of a derivative (code M) at $0.00 per share. To cover tax withholding, 17,984 of the newly issued shares were surrendered to the issuer at $5.50 per share, generating $98,912 (code F). Net new shares retained by Garg from this vesting event: 24,066.

Key Details

• Transaction date: January 25, 2026; Form filed January 27, 2026 (appears timely).
• Conversion: 42,050 shares acquired via RSU conversion (M) at $0.00 per share.
• Tax withholding: 17,984 shares surrendered to issuer (F) at $5.50/share for $98,912.
• Net shares received: 42,050 − 17,984 = 24,066 shares added to holdings.
• Shares beneficially owned after the transaction: not specified in the provided filing excerpt.
• Footnotes: F1 = each RSU converts to one common share when vested; F2 = surrendered shares solely to cover taxes; F3 = RSUs vest in substantially equal annual installments over four years from Jan 25, 2024.

Context
This was a vesting/conversion of RSUs rather than a cash purchase or open-market sale. The share surrender is a common, administrative tax-withholding method (not a market sale) and does not necessarily indicate a change in the director’s market view. The filing reflects conversion of a derivative award into shares and the customary withholding to satisfy tax obligations.